tiprankstipranks
Advertisement
Advertisement

MIRM Stock Latest News

Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)
The FlyMirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)
5h ago
MIRM
Mirum Pharmaceuticals Signals Growth Amid Heavy Investment
PremiumCompany Announcements
Mirum Pharmaceuticals Signals Growth Amid Heavy Investment
6h ago
MIRM
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $140 from $130 at Morgan Stanley
2d ago
MIRM
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright
3d ago
MIRM
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial
PremiumCompany Announcements
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial
3d ago
8K
MIRM
Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat
PremiumThe FlyMirum announces primary endpoint met in VISTAS Phase 2b study of volixibat
3d ago
MIRM
Mirum Pharmaceuticals price target raised to $130 from $125 at Stifel
Premium
The Fly
Mirum Pharmaceuticals price target raised to $130 from $125 at Stifel
8d ago
MIRM
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
Premium
The Fly
Mirum Pharmaceuticals price target raised to $112 from $95 at Baird
9d ago
MIRM
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright
10d ago
MIRM
Mirum’s brelovitug succeeds in Phase 2b HDV trial
PremiumCompany Announcements
Mirum’s brelovitug succeeds in Phase 2b HDV trial
10d ago
8K
MIRM
Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
PremiumThe Fly
Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study
10d ago
MIRM
Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC
PremiumRatings
Mirum Therapeutics: Favorable Risk/Reward Ahead of Key 2Q26 VISTAS Readout for Volixibat in PSC
1M ago
MIRM
Mirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen
PremiumThe FlyMirum Pharmaceuticals price target raised to $125 from $117 at TD Cowen
1M ago
MIRM
Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion
Premium
Ratings
Buy Rating on Mirum Pharmaceuticals Driven by Volixibat’s Differentiated IBAT Profile, Favorable PBC Market Dynamics, and Upside from PSC Expansion
1M ago
MIRM
Mirum Pharmaceuticals completes enrollment in EXPAND study
Premium
The Fly
Mirum Pharmaceuticals completes enrollment in EXPAND study
2M ago
MIRM
Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study
PremiumThe Fly
Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study
2M ago
MIRM
Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI
PremiumThe Fly
Mirum Pharmaceuticals price target raised to $126 from $101 at Evercore ISI
2M ago
MIRM
Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M
PremiumThe Fly
Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M
2M ago
MIRM
Mirum Pharmaceuticals sees FY26 global net product sales $630M-$650M
PremiumThe Fly
Mirum Pharmaceuticals sees FY26 global net product sales $630M-$650M
2M ago
MIRM
Mirum Pharmaceuticals falls -16.5%
PremiumThe FlyMirum Pharmaceuticals falls -16.5%
2M ago
MIRM
Mirum Pharmaceuticals price target raised to $130 from $123 at Morgan Stanley
Premium
The Fly
Mirum Pharmaceuticals price target raised to $130 from $123 at Morgan Stanley
2M ago
MIRM
Mirum Pharmaceuticals price target raised to $117 from $115 at TD Cowen
Premium
The Fly
Mirum Pharmaceuticals price target raised to $117 from $115 at TD Cowen
2M ago
MIRM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >